Mode of Action | Pharmacology | Pharmacokinetics | Safety & Tolerability | Receptor Affinity | Hardness | Duration | First Dose Success | Reliability | Fast Onset | PERT | ED & Diabetes | ED & Hypertension | ED & Dyslipidemia | ED & Metabolic Syndrome | ED & Radical Prostatectomy | ED & The Role of Female Partner

Treatment Options

Levitra- Pharmacokinetics

Pharmacokinetic parameters of the main PDE-5 inhibitors1

Pharmacokinetic parameters of the main PDE-5 inhibitors

CYP, cytochrome P450; nd, not determined; PDE-5, phosphodiesterase type 5; tmax, time to reach maximum drug plasma concentration; t1/2, elimination half life; Vd, volume of distribution

References:
1. Blount MA et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol. 2004 Jul;66(1):144-52.

Please Log in
Free registration to access disease diagnosis, patient management, physician tools.

Only registered users have access to this content.

Already Registered?

Email    Password   

Not a member?

Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students. 

Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major theraputic areas, disease management, and clinical tools.

As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!

REGISTER today it only takes a minute! and it's FREE

If you are not a healthcare professional please visit our patient site.

Having problems?

Use our forgotten password facility or email us at: contact@epgonline.org

Exit Log in